Fitch: Collateralized Commercial Paper Loses Traction

NEW YORK--(BUSINESS WIRE)-- Link to Fitch Ratings' Report: Collateralized Commercial Paper Loses Tractionhttps://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=873371

The number of collateralized commercial paper programs (CCP) and total CCP outstanding peaked in February 2014, according to a report issued by Fitch Ratings. Since then, CCP outstanding has fallen by 43%, despite the seeming attractiveness of the product for banks looking to diversify funding and money market funds attracted new sources of investment supply. The report discusses the instrument's structure and uses from the perspective of banks as issuers and money funds as investors.

In the CCP structure, financing facilities are collateralized through a special purpose vehicle (SPV). Debt is issued to investors in the form of CCP with terms that range from 1 to 397 days. CCP is typically either guaranteed by a bank and carries the bank's short-term rating or is issued by a rated subsidiary of the bank and carries the subsidiary's short-term rating. The SPV enters into repurchase agreements (repo) with the bank's broker dealer subsidiary. Investors in CCP notes provide the funding for the repo and the repo assets in turn are used as collateral for the CCP, creating a secured instrument. The purchased assets can be traditional government securities or non-traditional assets such as equities, corporate bonds and convertibles.

Money fund investment in CCP provides banks with the opportunity to finance greater amounts of repo assets for terms greater than seven days than would be possible under traditional term repo arrangements. The SEC's Rule 2a7 deems repos maturing in more than seven days as illiquid holdings, a category which is restricted to 5% of a fund's portfolio. However, CCP is deemed liquid under Rule 2a7 and therefore not subject to the 5% restriction.

In addition to lengthening repo terms, the CCP structure may permit banks to broaden the potential base of investors, conserve existing capacity or offset reduced capacity in the traditional repo market or other short-term markets, and potentially allows the bank to offer more customized terms.

The report, "Collateralized Commercial Paper Loses Traction" is available at www.fitchratings.com or by clicking the link above.

Opt-in to receive Fitch's forthcoming research on closed-end funds:

http://pages.fitchemail.fitchratings.com/FAMCEFBlankOptin/

Additional information is available at 'www.fitchratings.com'.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151209006444/en/

Fitch Ratings
Funds and Asset Management
Ralph R. Aurora
+1-212-908-0528
Greg Fayvilevich
+1-212-908-9151
or
Financial Institutions
Meghan Neenan
+1-212-908-9121
Christopher Wolfe
+1-212-908-0771
or
Media Relations
Hannah James, +1 646-582-4947
[email protected]

Source: Fitch Ratings

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Erasca proposes $500M common stock public offering
• Q32 Bio launches $200M stock offering to fund clinical trials